Murphy & Mullick Capital Management Corp Buys Shares of 6,162 Novo Nordisk A/S (NYSE:NVO)

Murphy & Mullick Capital Management Corp bought a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,162 shares of the company's stock, valued at approximately $530,000.

Other institutional investors have also modified their holdings of the company. GQG Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $404,910,000. Sustainable Growth Advisers LP lifted its position in shares of Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock worth $459,416,000 after buying an additional 1,021,498 shares during the last quarter. Amundi boosted its position in Novo Nordisk A/S by 26.4% during the fourth quarter. Amundi now owns 3,311,456 shares of the company's stock worth $283,615,000 after purchasing an additional 692,567 shares during the period. Finally, Parnassus Investments LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at $51,072,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $0.81 during mid-day trading on Friday, hitting $69.36. 5,852,065 shares of the stock were exchanged, compared to its average volume of 5,563,763. Novo Nordisk A/S has a twelve month low of $69.18 and a twelve month high of $148.15. The stock's fifty day simple moving average is $82.33 and its two-hundred day simple moving average is $99.11. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market cap of $311.23 billion, a P/E ratio of 21.08, a PEG ratio of 0.90 and a beta of 0.42.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio (DPR) is presently 47.72%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NVO. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S has an average rating of "Moderate Buy" and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.